Current Report Filing (8-k)
November 23 2016 - 6:08AM
Edgar (US Regulatory)
FORM
8-K
CURRENT
REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): November 17, 2016
SECOND
SIGHT MEDICAL PRODUCTS, INC.
|
(Exact
Name of Registrant as Specified in Its Charter)
|
|
California
|
(State
or Other Jurisdiction of Incorporation)
|
|
|
333-198073
|
|
|
02-0692322
|
|
|
(Commission
File Number)
|
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
12744
San Fernando Road, Suite 400
Sylmar, California 91342
|
(Address
of Principal Executive Offices)
|
|
(818)
833-5000
|
(Registrant's
Telephone Number, Including Area Code)
|
|
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM
8.01 Other Events
On November
17, 2016, the Agency for Healthcare Research and Quality (AHRQ), which is an agency of the Department of Health and Human Services,
published a technology assessment entitled “Retinal Prosthesis in the Medicare Population.” The technology assessment
provides an overview of multiple types of retinal prosthetic devices including the Argus II, and examined the available clinical
evidence for each. The technology assessment concluded that some patients clearly benefit from retinal prostheses and future studies
of retinal prosthesis should make an effort to report valid and reliable measures of day-to-day function and quality of life.
Further, the assessment concluded that for these patients, no other intervention exists to address their vision problems, so even
small gains may be considered important for clinical and policy decision making. No assurance can be given as to what impact,
if any, this report may have on Second Sight Medical Products, Inc. The report, which is dated September 30, 2016, can be accessed
at the following web site: (https://www.cms.gov/Medicare/Coverage/DeterminationProcess/downloads/id103TA.pdf). The foregoing
summary is qualified in its entirety by reference to that report.
To date our Argus II Retinal Prosthesis System
remains the only FDA approved and commercially available Retinal Prosthesis for the treatment of retinitis pigmentosa.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
November 22, 2016
SECOND
SIGHT MEDICAL PRODUCTS, INC.
/s/
Thomas B. Miller
|
|
By: Thomas B. Miller
|
|
Chief
Financial Officer
|
|
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Mar 2024 to Apr 2024
Second Sight Medical Pro... (NASDAQ:EYES)
Historical Stock Chart
From Apr 2023 to Apr 2024